(Q40614547)

22 September 2017

Imatinib mesylate (STI571) inhibits multiple myeloma cell proliferation and potentiates the effect of common antimyeloma agents (English)

1 reference

22 September 2017

1 reference

5

1 reference

22 September 2017

Xonia Carvajal-Vergara

object named as

Xonia Carvajal-Vergara

2

0 references

Atanasio Pandiella

1

object named as

Atanasio Pandiella

1 reference

22 September 2017

Soraya Tabera

3

1 reference

22 September 2017

Gema Mateo

4

1 reference

22 September 2017

Jesús F San Miguel

6

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

British Journal of Haematology

22 September 2017

1 reference

22 September 2017

123

1 reference

22 September 2017

858-868

1 reference

22 September 2017

5

1 reference

Moving disease biology from the lab to the clinic

22 September 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

The AKT kinase is activated in multiple myeloma tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Genetics of myeloid leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Novel targeted therapies for Bcr-Abl positive acute leukemias: beyond STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Mitogen-activated protein kinase pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Mitogen-activated protein kinases: specific messages from ubiquitous messengers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

Expression of the CD117 antigen (c-Kit) on normal and myelomatous plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04706.X

10.1046/J.1365-2141.2003.04706.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference